loading
Precedente Chiudi:
$8.36
Aprire:
$8.35
Volume 24 ore:
61,405
Relative Volume:
0.03
Capitalizzazione di mercato:
$510.54M
Reddito:
-
Utile/perdita netta:
$-130.41M
Rapporto P/E:
-3.2393
EPS:
-2.57
Flusso di cassa netto:
$-67.76M
1 W Prestazione:
-1.89%
1M Prestazione:
+52.66%
6M Prestazione:
+93.71%
1 anno Prestazione:
+179.19%
Intervallo 1D:
Value
$8.17
$8.48
Intervallo di 1 settimana:
Value
$7.40
$8.63
Portata 52W:
Value
$2.9106
$12.40

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name
Nome
Monte Rosa Therapeutics Inc
Name
Telefono
617-949-2643
Name
Indirizzo
321 HARRISON AVENUE, BOSTON
Name
Dipendente
103
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
GLUE's Discussions on Twitter

Confronta GLUE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
GLUE 8.35 510.54M 0 -130.41M -67.76M -2.57
VRTX 445.32 115.74B 10.63B -479.80M -1.35B 13.33
REGN 736.78 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 584.00 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 247.00 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.17 24.49B 3.30B -501.07M 1.03B 11.54

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-01-03 Aggiornamento Wells Fargo Equal Weight → Overweight
2022-10-13 Iniziato UBS Buy
2022-08-15 Iniziato Jefferies Buy
2022-04-28 Iniziato Credit Suisse Neutral
2022-02-10 Iniziato Wells Fargo Equal Weight
2021-10-14 Iniziato SVB Leerink Mkt Perform
Mostra tutto

Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie

pulisher
Nov 20, 2024

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet - MSN

Nov 20, 2024
pulisher
Nov 16, 2024

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024
pulisher
Nov 13, 2024

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Monte Rosa Therapeutics to Present at Jefferies Healthcare Conference: MGD Innovation Spotlight | GLUE Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

FMR LLC Increases Stake in Monte Rosa Therapeutics Inc - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts - Simply Wall St

Nov 12, 2024
pulisher
Nov 11, 2024

Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), - Yahoo Finance

Nov 11, 2024
pulisher
Nov 11, 2024

Wedbush Equities Analysts Raise Earnings Estimates for GLUE - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Earns “Outperform” Rating from Wedbush - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

Monte Rosa Therapeutics Expands Pipeline with Novartis Deal - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics: Q3 Earnings Snapshot - Barchart

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics Inc (GLUE) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Secures $2.1B Novartis Deal, Extends Cash Runway to 2028 in Major Pipeline Win | GLUE Stock News - StockTitan

Nov 07, 2024
pulisher
Oct 31, 2024

Equities Analysts Issue Forecasts for GLUE FY2024 Earnings - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

Wedbush Research Analysts Lift Earnings Estimates for GLUE - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa, Novartis Partner To Advance Molecular Glue Degraders - Contract Pharma

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

This Biotech Stock Has Doubled Its Value Today—Here's Why - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics Soars on Novartis Deal: A Molecular Glue Revolution - BP Journal

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics stock hits 52-week high at $8.87 By Investing.com - Investing.com Canada

Oct 29, 2024
pulisher
Oct 28, 2024

Novartis adds another degrader, this time from Monte Rosa - BioCentury

Oct 28, 2024
pulisher
Oct 28, 2024

This Biotech Almost Doubled On A Massive Deal With Novartis - Investor's Business Daily

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 52-Week HighTime to Buy? - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa, Novartis have one in VAV1, sign $2.1B pact - BioWorld Online

Oct 28, 2024
pulisher
Oct 28, 2024

Boston Biotech Announces Novartis Collaboration - Streetwise Reports

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics Target of Unusually High Options Trading (NASDAQ:GLUE) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics More Than Doubles on Novartis Agreement - MarketWatch

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis - MSN

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash (NASDAQ:GLUE) - Seeking Alpha

Oct 28, 2024
pulisher
Oct 28, 2024

Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics - BioPharm International

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa's stock doubles on multibillion dollar Novartis deal - The Business Journals

Oct 28, 2024
pulisher
Oct 28, 2024

Top Gainer Monte Rosa Therapeutics’ Stock Enthralls Retail With Novartis Licensing Deal - Barchart

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics stock hits 52-week high at $8.87 - Investing.com India

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa scores $2.1B Novartis deal for molecular glue degraders - BioWorld Online

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa soars as it inks global license deal with Novartis - The Pharma Letter

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa joins with Novartis in ‘molecular glue’ drug deal - BioPharma Dive

Oct 28, 2024
pulisher
Oct 28, 2024

“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics, Inc Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - Marketscreener.com

Oct 28, 2024
pulisher
Oct 28, 2024

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs - Reuters

Oct 28, 2024
pulisher
Oct 28, 2024

Why Is Monte Rosa Therapeutics Stock Surging On Monday? - Yahoo Finance

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics Shares Soar on Novartis Team-Up - Marketscreener.com

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa jumps on $150M license deal with Novartis (NASDAQ:GLUE) - Seeking Alpha

Oct 28, 2024

Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):